Zestoretic is a fixed-dose combination of lisinopril and hydrochlorothiazide, paired in a single oral preparation for the management of hypertension. Combining an agent that acts on the renin-angiotensin system with a diuretic is a long-established backbone of antihypertensive therapy, and combination products like Zestoretic formalise a pairing that clinicians frequently prescribe as two separate tablets.
Lisinopril belongs to the broader category of agents acting in the renin-angiotensin system, contributing the antihypertensive action that targets vascular tone through that pathway. Hydrochlorothiazide is a diuretic, working through a separate mechanism centred on fluid and electrolyte handling. The two complementary mechanisms acting at once is what gives this kind of combination its place in blood-pressure management, and it can also simplify daily medication routines for patients who would otherwise take the ingredients separately.
Zestoretic is marketed in 25 countries, with a footprint that spans Western Europe, the Americas, the Middle East, and parts of Asia. Examples include Brazil, France, Egypt, Canada, and Hong Kong. Travellers and expatriates moving between these regions may encounter Zestoretic under the same name, while in other markets the same two-ingredient combination is sold under different brand names or assembled from separate single-ingredient products.
Combination antihypertensives vary across countries more than single-ingredient drugs, both in the specific dose ratios offered and in which combinations a national formulary supports. A pharmacist in the destination country is well placed to identify whether a comparable lisinopril-and-hydrochlorothiazide product is available locally. Decisions about starting, continuing, or substituting any blood-pressure medication belong with the prescribing healthcare provider rather than with the pharmacy counter.
Zestoretic is prescribed for the management of hypertension, or high blood pressure. It pairs two ingredients that act through different mechanisms — one targeting the renin-angiotensin system and the other acting as a diuretic — which is a long-established approach in antihypertensive therapy. The structured indication section further down this page lists the registered uses recognised across the markets where Zestoretic is sold.
Zestoretic contains two active ingredients: lisinopril, which acts on the renin-angiotensin system, and hydrochlorothiazide, a diuretic. Both molecules are independently available worldwide under numerous brand names, and the pairing of an agent in lisinopril's class with a thiazide diuretic is a common combination strategy in antihypertensive therapy formalised here in a single tablet.
Zestoretic carries marketing authorisation in 25 countries spread across Europe, the Americas, the Middle East, and parts of Asia. Representative markets include Brazil, Canada, France, Egypt, Hong Kong, and Norway. If your country is not represented in the list shown on this page, a local pharmacist can usually confirm whether a comparable lisinopril-and-hydrochlorothiazide product is available under a different brand name.
Lisinopril and hydrochlorothiazide are each sold worldwide under many brand names, both as single-ingredient products and as fixed-dose combinations from various manufacturers. Other medications in the broader antihypertensive and diuretic categories also exist, although they are not interchangeable without medical guidance. To identify a regional equivalent, search either active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Zestoretic is a prescription medication, and antihypertensive therapy is calibrated to each patient's blood pressure profile, kidney function, concurrent medications, and broader medical history. This is particularly relevant for travellers and people relocating between countries, where prescription rules, available combinations, and brand names differ. Any decision to start, stop, switch, or substitute should be made with a healthcare provider familiar with the patient.
